These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29696406)

  • 21. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
    Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
    Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives.
    Palle J; Rochand A; Pernot S; Gallois C; Taïeb J; Zaanan A
    Drugs; 2020 Mar; 80(4):401-415. PubMed ID: 32077003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M; Shojaei S; Kaviani A; Behnam B
    Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
    Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
    J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic Response of HER2-positive Gastric Cancer to Trastuzumab-based Chemotherapy.
    Urabe M; Ushiku T; Seto Y; Fukayama M
    Am J Surg Pathol; 2016 Oct; 40(10):1326-33. PubMed ID: 27259008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. α-linolenic acid and docosahexaenoic acid, alone and combined with trastuzumab, reduce HER2-overexpressing breast cancer cell growth but differentially regulate HER2 signaling pathways.
    Mason JK; Klaire S; Kharotia S; Wiggins AK; Thompson LU
    Lipids Health Dis; 2015 Aug; 14():91. PubMed ID: 26282560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
    Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
    Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CMIP promotes Herceptin resistance of HER2 positive gastric cancer cells.
    Xiang R; Han X; Ding K; Wu Z
    Pathol Res Pract; 2020 Feb; 216(2):152776. PubMed ID: 31822364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.
    Arienti C; Zanoni M; Pignatta S; Del Rio A; Carloni S; Tebaldi M; Tedaldi G; Tesei A
    Oncotarget; 2016 Apr; 7(14):18424-39. PubMed ID: 26919099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
    Ding X; Qu X; Fan Y; Che X; Qu J; Xu L; Liu J; Liu Y
    Anticancer Drugs; 2014 Mar; 25(3):315-22. PubMed ID: 24300914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
    Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
    Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
    Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
    Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2-positive advanced gastric cancer.
    Kunzke T; Hölzl FT; Prade VM; Buck A; Huber K; Feuchtinger A; Ebert K; Zwingenberger G; Geffers R; Hauck SM; Haffner I; Luber B; Lordick F; Walch A
    Clin Transl Med; 2021 Sep; 11(9):e547. PubMed ID: 34586736
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of trastuzumab on the proliferation and apoptosis of ovarian cancer cells.
    Cong J; Liu R; Hou J; Wang X; Jiang H; Wang J
    Neoplasma; 2019 Mar; 66(2):240-244. PubMed ID: 30509111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.